hotspot -WSS

hotspot

author：entertainment 2025-09-27 17:02:26 - browse：39172

Illustration of a red heart. -- health coverage from STAT — Adobe

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy.

The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular benefits. The company reported only the topline figure in a press release Tuesday, and did not break out the reductions it said were seen in heart attacks, strokes, and cardiovascular deaths — the combined components of the study’s primary outcome. It said all three contributed to the decrease in cardiovascular events in the group that received Wegovy compared with participants given a placebo.

The 20% reduction was greater than many observers were expecting. In a research note Tuesday, Jefferies analysts called the results a “best case” outcome. “If they play baseball in Denmark,” Barclays analyst Emily Field wrote in a note, “Wegovy just hit a home run.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Head of FDA's diagnostics center, who led through Covid, retires

entertainment

WSS

Morgan Health, with ambitious aims, wants you to know it’s still here

Update the Apgar Score to remove skin color

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

A pediatrician calls for Congress to pass the child tax credit deal

TikTok, Instagram influencers need more rules for drug ads

CVS is on a mission to consolidate health care. Will it work?

explore

hotspot

leisure time

Supreme Court strikes down use of affirmative action

Pumping milk in bathrooms at health conferences is common

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

In age of alternative facts, a scholarly course on calling out crap

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

CVS is on a mission to consolidate health care. Will it work?

DIEP, the 'gold standard' of breast reconstruction, is under threat

A pediatrician calls for Congress to pass the child tax credit deal

entertainment

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Cardiologists urge adding sexual orientation, gender identity to health records

A single drug, study failures leave Anavex with nothing but cash

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

FDA sets aggressive timeline for overhauling inspection procedures

Cardiologists urge adding sexual orientation, gender identity to health records

knowledge

hotspot

entertainment

focus